The transcription factor FOXO4 is down-regulated and inhibits tumor proliferation and metastasis in gastric cancer

BMC Cancer

Daiming Fan²  Yongquan Shi²  Yongzhan Nie²  Xiaosa Li²  Rui Wang²  Lifen Lv²  Na Chai¹  Xiangqiang Liu²  Linna Su² 

[1]Department of Radiology, Xijing Hospital, Fourth Military Medical University, 127 Changle Western Road, Xi’an, Shaanxi Province 710032, People’s Republic of China

[2]State Key Laboratory of Cancer Biology & Xijing Hospital of Digestive Diseases, The Fourth Military Medical University, 127 Changle Western Road, Xi’an, Shaanxi Province 710032, People’s Republic of China

关键词: EMT;    Metastasis;    Proliferation;    Gastric cancer;    FOXO4;   

Others  :  858780
DOI  :  10.1186/1471-2407-14-378

 received in 2014-01-14, accepted in 2014-05-20,  发布年份 2014

【 摘 要 】

Background

FOXO4, a member of the FOXO family of transcription factors, is currently the focus of intense study. Its role and function in gastric cancer have not been fully elucidated. The present study was aimed to investigate the expression profile of FOXO4 in gastric cancer and the effect of FOXO4 on cancer cell growth and metastasis.

Methods

Immunohistochemistry, Western blotting and qRT-PCR were performed to detect the FOXO4 expression in gastric cancer cells and tissues. Cell biological assays, subcutaneous tumorigenicity and tail vein metastatic assay in combination with lentivirus construction were performed to detect the impact of FOXO4 to gastric cancer in proliferation and metastasis in vitro and in vivo. Confocal and qRT-PCR were performed to explore the mechanisms.

Results

We found that the expression of FOXO4 was decreased significantly in most gastric cancer tissues and in various human gastric cancer cell lines. Up-regulating FOXO4 inhibited the growth and metastasis of gastric cancer cell lines in vitro and led to dramatic attenuation of tumor growth, and liver and lung metastasis in vivo, whereas down-regulating FOXO4 with specific siRNAs promoted the growth and metastasis of gastric cancer cell lines. Furthermore, we found that up-regulating FOXO4 could induce significant G1 arrest and S phase reduction and down-regulation of the expression of vimentin.

Conclusion

Our data suggest that loss of FOXO4 expression contributes to gastric cancer growth and metastasis, and it may serve as a potential therapeutic target for gastric cancer.

【 授权许可】

   
2014 Su et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [2]Jiang Y, Wang L, Gong W, Wei D, Le X, Yao J, Ajani J, Abbruzzese JL, Huang S, Xie K: A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer. Clin Exp Metastasis 2004, 21(8):755-764.
• [3]Kajita Y, Kato T Jr, Tamaki S, Furu M, Takahashi R, Nagayama S, Aoyama T, Nishiyama H, Nakamura E, Katagiri T, Nakamura Y, Ogawa O, Toguchida J: The transcription factor Sp3 regulates the expression of a metastasis-related marker of sarcoma, actin filament-associated protein 1-like 1 (AFAP1L1). PloS one 2013, 8(1):e49709.
• [4]Zhang H, Meng F, Liu G, Zhang B, Zhu J, Wu F, Ethier SP, Miller F, Wu G: Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis. Cancer Res 2011, 71(4):1292-1301.
• [5]Atreya I, Schimanski CC, Becker C, Wirtz S, Dornhoff H, Schnurer E, Berger MR, Galle PR, Herr W, Neurath MF: The T-box transcription factor eomesodermin controls CD8 T cell activity and lymph node metastasis in human colorectal cancer. Gut 2007, 56(11):1572-1578.
• [6]Sykes SM, Lane SW, Bullinger L, Kalaitzidis D, Yusuf R, Saez B, Ferraro F, Mercier F, Singh H, Brumme KM, Acharya SS, Scholl C, Tothova Z, Attar EC, Frohling S, DePinho RA, Armstrong SA, Gilliland DG, Scadden DT: AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 2011, 146(5):697-708.
• [7]Daitoku H, Sakamaki J, Fukamizu A: Regulation of FoxO transcription factors by acetylation and protein-protein interactions. Biochim Biophys Acta 2011, 1813(11):1954-1960.
• [8]Maiese K, Chong ZZ, Shang YC: OutFOXOing disease and disability: the therapeutic potential of targeting FoxO proteins. Trends Mol Med 2008, 14(5):219-227.
• [9]van der Vos KE, Coffer PJ: FOXO-binding partners: it takes two to tango. Oncogene 2008, 27(16):2289-2299.
• [10]Watroba M, Maslinska D, Maslinski S: Current overview of functions of FoxO proteins, with special regards to cellular homeostasis, cell response to stress, as well as inflammation and aging. Adv Med Sci 2012, 57(2):183-195.
• [11]Zhu J, Mounzih K, Chehab EF, Mitro N, Saez E, Chehab FF: Effects of FoxO4 overexpression on cholesterol biosynthesis, triacylglycerol accumulation, and glucose uptake. J Lipid Res 2010, 51(6):1312-1324.
• [12]Liu X, Zhang Z, Sun L, Chai N, Tang S, Jin J, Hu H, Nie Y, Wang X, Wu K, Jin H, Fan D: MicroRNA-499-5p promotes cellular invasion and tumor metastasis in colorectal cancer by targeting FOXO4 and PDCD4. Carcinogenesis 2011, 32(12):1798-1805.
• [13]Zhang Y, Gan B, Liu D, Paik JH: FoxO family members in cancer. Cancer Biol Ther 2011, 12(4):253-259.
• [14]Zhang X, Tang N, Hadden TJ, Rishi AK: Akt, FoxO and regulation of apoptosis. Biochim Biophys Acta 2011, 1813(11):1978-1986.
• [15]Kleindorp R, Flachsbart F, Puca AA, Malovini A, Schreiber S, Nebel A: Candidate gene study of FOXO1, FOXO4, and FOXO6 reveals no association with human longevity in Germans. Aging Cell 2011, 10(4):622-628.
• [16]Iyer S, Ambrogini E, Bartell SM, Han L, Roberson PK, de Cabo R, Jilka RL, Weinstein RS, O'Brien CA, Manolagas SC, Almeida M: FOXOs attenuate bone formation by suppressing Wnt signaling. J Clin Invest 2013, 123(8):3409-3419.
• [17]Bullock MD, Sayan AE, Packham GK, Mirnezami AH: MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol Cell 2012, 104(1):3-12.
• [18]Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Canc 2002, 2(6):442-454.
• [19]Spaderna S, Schmalhofer O, Hlubek F, Berx G, Eger A, Merkel S, Jung A, Kirchner T, Brabletz T: A transient, EMT-linked loss of basement membranes indicates metastasis and poor survival in colorectal cancer. Gastroenterology 2006, 131(3):830-840.